Olfactory Receptor 2B11 as A Potential Drug Target for Insomnia and Smell Perception
Olfactory Receptor 2B11 as A Potential Drug Target for Insomnia and Smell Perception
Olfactory receptor family 2 (OR2) is a family of transmembrane G protein-coupled receptors (GPCRs) that play a crucial role in sensory function, particularly smell and taste. The OR2 receptor family consists of 15 known genes, including Olfactory receptor family 2 subfamily B member 11 (OR2B11), which is a GPCR that is expressed in the olfactory system. OR2B11 is a 21-kDa protein that is expressed in the olfactory nerve and is involved in the perception of odors.
OR2B11 is a GPCR that is characterized by its extracellular domain, which is composed of a helix-containing region and a cytoplasmic tail. The N-terminus of OR2B11 contains a 尾-sheet, which is a common structural motif that is found in many GPCRs. The 尾-sheet is responsible for the stability and localization of the OR2B11 protein.
The OR2B11 protein is composed of 1,222 amino acid residues, and its molecular weight is 21 kDa. OR2B11 is predominantly expressed in the olfactory system, including the olfactory nerve, the vomiting cord, and the interdigital sweat glands. It is also expressed in the skin, heart, liver, and brain.
OR2B11 is involved in the perception of odors. It is a critical receptor for the neurotransmitter ethyl acetate (EtOH), which is produced by the sephences of the vomiting cord. EetOH is known to play a crucial role in the sensation of food and drink. OR2B11 is also involved in the perception of other odors, such as those associated with danger, pheromones, and environmental stimuli.
OR2B11 is a potential drug target in the treatment of various disorders associated with the sense of smell, including but not limited to, Alzheimer's disease, Parkinson's disease, and chronic insomnia. These disorders are characterized by a decline in the ability to perceive and tolerate odors, leading to a decline in quality of life.
OR2B11 is also a potential biomarker for various diseases associated with the sense of smell. For example, decreased OR2B11 expression has been observed in the brains of individuals with Alzheimer's disease, which is a leading cause of dementia. Similarly, decreased OR2B11 expression has also been observed in the brains of individuals with Parkinson's disease, a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain.
In addition to its potential drug and biomarker applications, OR2B11 also has potential as a therapeutic target for the treatment of chronic insomnia. Chronic insomnia is a common sleep disorder that is characterized by a persistent lack of sleep and waking up too early or too late. Chronic insomnia has been associated with various psychiatric and physiological disorders, including cardiovascular disease, diabetes, and depression.
OR2B11 is involved in the regulation of insomnia by the neurotransmitter GABA, which is an inhibitory neurotransmitter that plays a crucial role in the regulation of sleep. OR2B11 has been shown to interact with GABA and modulate its activity, which may contribute to its role in the regulation of insomnia.
In conclusion, OR2B11 is a GPCR that is involved in the perception of odors and is a potential drug target and biomarker for various disorders associated with the sense of smell, including Alzheimer's disease, Parkinson's disease, and chronic insomnia. Further research is needed to fully understand the role of OR2B11 in
Protein Name: Olfactory Receptor Family 2 Subfamily B Member 11
Functions: Odorant receptor
The "OR2B11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2B11 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3
